Renáta Váraljai
11PUBLICATIONS
43CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Jan 15, 2025
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.Sara Egea-Rodriguez, Renáta Váraljai, Thierry M Nordmann
|Aug 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary
|Jul 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary
|Nov 02, 2022
Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.Lea Jessica Albrecht, Anna Höwner, Klaus Griewank
|Jun 01, 2022
Persister state-directed transitioning and vulnerability in melanoma.Heike Chauvistré, Batool Shannan, Sheena M Daignault-Mill
|Mar 25, 2022
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition.Luca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi
Pageof 2
Frequent Collaborators
6 joint publications
Dirk Schadendorf
5 joint publications
Alexander Roesch
3 joint publications
Annette Paschen
2 joint publications
Iris Helfrich
2 joint publications
Wiebke Sondermann
2 joint publications
Daniela S Thommen
2 joint publications
Elisabeth Livingstone
2 joint publications
Fang Zhao
2 joint publications
Jenny Dick
1 joint publications
Daniel Gusenleitner
